Compare Supplements

INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.

Any time

Oral tablet (investigational)

30grams

Any time · with food (preferred)

Whey Protein Isolate

• Not an approved medicine — only appropriate within a clinical trial or, if/when approved, under a clinician
• Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern
• History of pancreatitis (caution, consistent with the GLP-1 class)

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Milk allergy (use plant-based alternatives)
• Severe lactose intolerance (use isolate or lactose-free)

• Levodopa
• Levothyroxine
• Alendronate (bisphosphonates)